Novus Biologicals products are now on bio-techne.com

Recombinant Human CXCL5/ENA-78 Protein

Images

 
There are currently no images for CXCL5/ENA-78 (254-XB).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human CXCL5/ENA-78 Protein Summary

Details of Functionality
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR2. The ED50 is 3-15 ng/mL
Source
E. coli-derived human CXCL5/ENA-78 protein
Ala37-Asn114
Accession #
N-terminal Sequence
Ala37
Protein/Peptide Type
Recombinant Proteins
Gene
CXCL5
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity2
Theoretical MW
8.4 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
7 kDa, reducing conditions
Publications
Read Publications using
254-XB in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS containing BSA as carrier protein
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CXCL5/ENA-78 Protein

  • chemokine (C-C motif) ligand 5
  • C-X-C motif chemokine 5
  • CXCL5
  • CXCL5/ENA-78
  • ENA78
  • ENA-78
  • ENA-78(1-78)
  • Epithelial-derived neutrophil-activating protein 78
  • Neutrophil-activating peptide ENA-78
  • neutrophil-activating protein 78
  • SCYB5ENA78

Background

CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR-CXC chemokines which are angiostatic (1-3). Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP-2 and 35%-51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP-2, and CXCL8/IL-8. Inflammatory stimulation up-regulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis (3-6). Its up-regulation contributes to increased vascularization, tumor growth, and metastasis in many cancers (6-9). Full length CXCL5 (78 aa) is trimmed at the N-terminus by cathepsin G and chymotrypsin to ENA-74 (74 aa) and ENA-70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5 (10, 11). CXCL5 exerts its effects primarily through interactions with CXCR2 (6, 12). It also binds duffy antigen receptor for chemokines (DARC), which can limit CXCR2-mediated responses (13, 14).

  1. Strieter, R.M. et al. (2005) Cytokine Growth Factor Rev. 16:593.
  2. Balestrieri, M.L. et al. (2008) Cardiovasc. Res. 78:250.
  3. Walz, A.. et al. (1991) J. Exp. Med. 174:1355.
  4. Strieter, R.M. et al. (1992) Immunol. Invest. 21:549.
  5. Koch, A.E. et al. (1994) J. Clin. Invest. 94:1012.
  6. Begley, L.A. et al. (2008) Neoplasia 10:244.
  7. Vandercappellen, J. et al. (2008) Cancer Lett. 267:226.
  8. Arenberg, D.A. et al. (1998) J. Clin. Invest. 102:465.
  9. Miyazaki, H. et al. (2006) Cancer Res. 66:4279.
  10. Wuyts, A. et al. (1999) Eur. J. Biochem. 260:421.
  11. Nufer, O. et al. (1999) Biochemistry 38:636.
  12. Ahuja, S.K. and P.M. Murphy (1996) J. Biol. Chem. 271:20545.
  13. Kashiwazaki, M. et al. (2003) Int. Immunol. 15:1219.
  14. Horton, L.W. et al. (2007) Cancer Res. 67:9791.

Customers Who Viewed This Item Also Viewed...

MAB208
Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, ICFlow, Neut, Simple Western, WB
DY453
Species: Mu
Applications: ELISA
DCP00
Species: Hu
Applications: ELISA
MAB333
Species: Hu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut, WB
DRN00B
Species: Hu
Applications: ELISA
M6000B
Species: Mu
Applications: ELISA
DIP100
Species: Hu
Applications: ELISA
DY393
Species: Hu
Applications: ELISA
MM200
Species: Mu
Applications: ELISA
AF-492-NA
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut
MAB331
Species: Hu
Applications: CyTOF-ready, Flow, IHC, Neut
NBP1-81841
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
MAB330
Species: Hu
Applications: CyTOF-reported, Flow, IHC, Neut
201-LB
Species: Hu
Applications: BA
8297-GG/CF
Species: Hu
Applications: BA
DVE00
Species: Hu
Applications: ELISA
DY443
Species: Mu
Applications: ELISA
DY417
Species: Mu
Applications: ELISA
254-XB
Species: Hu
Applications: Bioactivity

Publications for CXCL5/ENA-78 (254-XB)(9)

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Bioassay.


Filter By Application
Bioassay
(9)
All Applications
Filter By Species
Human
(9)
All Species
Showing Publications 1 - 9 of 9.
Publications using 254-XB Applications Species
Chen, C;Lin, LY;Chen, JW;Chang, TT; CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus Cardiovascular diabetology 2023-07-07 [PMID: 37420254] (Bioassay, Human) Bioassay Human
C Wang, A Li, S Yang, R Qiao, X Zhu, J Zhang CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-?B pathway Biochem. Biophys. Res. Commun., 2018-03-17;0(0):. 2018-03-17 [PMID: 29545183] (Bioassay, Human) Bioassay Human
Gharaee-Kermani M, Mehra R, Robinson D, Wei J, Macoska J Complex cellular composition of solitary fibrous tumor of the prostate. Am J Pathol, 2014-01-13;184(3):732-9. 2014-01-13 [PMID: 24434011] (Bioassay, Human) Bioassay Human
Sundaram K, Rao D, Ries W, Reddy S CXCL5 stimulation of RANK ligand expression in Paget&#039;s disease of bone. Lab Invest, 2013-02-25;93(4):472-9. 2013-02-25 [PMID: 23439434] (Bioassay, Human) Bioassay Human
Interleukin-33 overexpression is associated with gamma-glutamyl transferase in biliary atresia. Cytokine, 2012-11-22;61(2):433-7. 2012-11-22 [PMID: 23178147] (Bioassay, Human) Bioassay Human
Staphylococcus aureus Staphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. EMBO J., 2012-07-31;31(17):3607-19. 2012-07-31 [PMID: 22850671] (Bioassay, Human) Bioassay Human
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human) Bioassay Human
Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am. J. Pathol., 2011-03-01;178(3):1340-9. 2011-03-01 [PMID: 21356384] (Bioassay, Human) Bioassay Human
Zhang H, Ning H, Banie L, Wang G, Lin G, Lue TF, Lin CS Adipose tissue-derived stem cells secrete CXCL5 cytokine with chemoattractant and angiogenic properties. Biochem. Biophys. Res. Commun., 2010-10-27;402(3):560-4. 2010-10-27 [PMID: 21034724] (Bioassay, Human) Bioassay Human

Reviews for CXCL5/ENA-78 (254-XB) (0)

There are no reviews for CXCL5/ENA-78 (254-XB). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for CXCL5/ENA-78 (254-XB) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional CXCL5/ENA-78 Products

Blogs on CXCL5/ENA-78

There are no specific blogs for CXCL5/ENA-78, but you can read our latest blog posts.
Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human CXCL5/ENA-78 Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol CXCL5
Uniprot